Myocardial Infarction
Amgen Builds Case for Repatha to Prevent Heart Disease With Landmark Late-Stage Data
Amgen; Repatha; VESALIUS-CV trial; primary prevention; cardiovascular disease; PCSK9 inhibitor; LDL-C; FDA approval; major adverse cardiovascular events; heart attack; stroke
Distinguishing Adverse Events from Complications in Heart Attacks
heart attack, adverse event, complication, cardiac health, medical emergency